TEVA PHARMACEUTICAL INDUSTRIES LTD
No SEC Form 4 filings for $TEVA in the last 30 days.
Veeva Systems (NYSE: VEEV) said Teva Pharmaceuticals has committed to deploy Veeva Vault CRM globally. Teva’s IT VP Lavanya Narasimhamurthy said the move will provide a technical foundation for commercial execution. Veeva President Tom Schwenger said Vault CRM includes an agentic call report for compliant evidence generation.
Truist Financial Corp reduced its stake in Teva Pharmaceutical Industries Ltd. by 30.5% in the fourth quarter, selling 296,745 shares and retaining 676,170 shares valued at $21.1 million. Other institutional investors like Horizon Investments LLC and Jennison Associates LLC also adjusted their positions, indicating varied sentiment towards the company. Teva Pharmaceutical Industries, a multinational pharmaceutical company focusing on generic medicines, has a "Moderate Buy" rating from analysts with a consensus target price of $41.78.
Teva Pharmaceutical Industries Ltd. announced that Eric Hughes, EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 12, 2026, at 9:20 A.M. Pacific Time. The presentation will be webcast live on Teva's Investor Relations website, with an archived version available for 30 days. The company's press release also includes a cautionary note regarding forward-looking statements.
